|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:ATCCode
|
L04AX02
|
|
gptkbp:brand
|
gptkb:Contergan
Thalomid
|
|
gptkbp:CASNumber
|
50-35-1
|
|
gptkbp:category
|
gptkb:World_Health_Organization_essential_medicines
orphan drugs
immunosuppressants
glutarimides
phthalimides
teratogens
|
|
gptkbp:chemicalFormula
|
C13H10N2O4
|
|
gptkbp:discoveredBy
|
gptkb:Chemie_Grünenthal
|
|
gptkbp:discoveredIn
|
gptkb:Germany
|
|
gptkbp:eliminationHalfLife
|
5–7 hours
|
|
gptkbp:firstMarketedIn
|
gptkb:Germany
|
|
gptkbp:hasEnantiomer
|
(R)-Thalidomide
(S)-Thalidomide
|
|
gptkbp:hasInChIKey
|
UEJJHQNACJXSKW-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
O=C1NC(=O)C2=CC=CC=C2C1=O.C1CCC(=O)NC1=O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Thalidomide
|
|
gptkbp:introducedIn
|
1957
|
|
gptkbp:IUPACName
|
2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
anti-angiogenic
immunomodulatory
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
258.23 g/mol
|
|
gptkbp:notableEvent
|
Thalidomide tragedy
|
|
gptkbp:notableFor
|
causing birth defects in 1950s-1960s
|
|
gptkbp:pregnancyCategory
|
X (contraindicated)
|
|
gptkbp:prescribes
|
gptkb:cancer
HIV-related conditions
leprosy complications
|
|
gptkbp:prohibits
|
pregnancy
|
|
gptkbp:regulates
|
REMS program (US)
|
|
gptkbp:regulatoryWarning
|
black box warning (US)
|
|
gptkbp:relatedTo
|
gptkb:lenalidomide
gptkb:pomalidomide
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
birth defects
peripheral neuropathy
|
|
gptkbp:teratogenic
|
true
|
|
gptkbp:UNII
|
4Z8R6ORS6L
|
|
gptkbp:usedFor
|
gptkb:erythema_nodosum_leprosum
multiple myeloma
|
|
gptkbp:withdrawn
|
1961
|
|
gptkbp:bfsParent
|
gptkb:Winter_Trees
|
|
gptkbp:bfsLayer
|
7
|